AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook

Amneal Pharmaceuticals AMRX enters 2026 with multiple levers working at once. Fiscal 2025 delivered broad-based revenue gains, rising profitability, and improving cash generation.

The setup for 2026 is not dependent on a single product cycle. It rests on a diversified business mix, an accelerating launch cadence in Affordable Medicines, and a strategic shift toward higher-value complex products.

AMRX Business Mix Sets a Resilient Base

Amneal’s three-segment structure helps stabilize results across market cycles. Affordable Medicines provides steady generic cash flows, Specialty offers higher-margin upside, and AvKARE adds a durable government channel that can balance volatility elsewhere.

That resilience is reinforced by a portfolio of roughly 300 medicines spanning complex generics, injectables, biosimilars, and specialty brands. The breadth reduces reliance on any single product and supports multiple paths to growth.

Amneal’s 2025 Results Show Broad-Based Momentum

Fiscal 2025 total net revenues rose 8.0% year over year to $3.0 billion, with all three segments contributing to the gain. Affordable Medicines generated $1.7 billion, or 57.8% of revenue, Specialty delivered $528.5 million, or 17.5%, and AvKARE produced $744.7 million, or 24.7%.

The growth was not limited to the top line. Adjusted EBITDA increased 10% in 2025 and adjusted earnings per share climbed 43%, supported by margin expansion and lower net interest costs. Adjusted gross margin expanded by about 50 basis points to roughly 43%.

AMRX Affordable Medicines Could Accelerate in 2026

Management expects Affordable Medicines net revenues to grow 7% to 8% in 2026, an acceleration versus the 2025 growth rate. The outlook is tied to an elevated pace of approvals and launches, including momentum from late-2025 introductions such as denosumab biosimilars and a generic version of Omnipaque (iohexol) injection.

The cadence matters because Affordable Medicines is designed to compound through volume and breadth. Amneal expects to launch 20 to 30 new products in the segment each year, helping refresh the portfolio and sustain growth even as individual products mature.

Amneal’s Pipeline Focus Is Shifting to Higher-Value Products

Amneal is increasingly pushing beyond traditional oral solid generics into complex generics, injectables, biosimilars, and peptide and sterile capabilities. That shift is meant to move the company up the value chain, where products can be harder to replicate and economics can be more attractive.

The strategy also creates additional growth drivers that sit alongside the core generics engine. A key example is the manufacturing and supply partnership with Pfizer supporting GLP-1 and related metabolic therapies, which is positioned as a scalable revenue stream without clinical development risk while strengthening Amneal’s injectable and peptide infrastructure.

AMRX Specialty Has a Near-Term Speed Bump

Specialty is expected to be roughly flat in 2026. The primary headwind is anticipated generic erosion of Rytary, following the launch of an authorized generic in 2025 and the expectation of additional generic entrants in 2026.

Even with that pressure, Amneal expects the segment to return to growth from 2027 as Crexont and additional brands scale. The 2026 setup is therefore more of a transition year than a thesis break, with continued Crexont growth expected to partially offset the Rytary dynamic.

Amneal’s Newer Brands Add Optionality to the Model

Specialty performance is being supported by robust uptake of Crexont and Unithroid. These brands are part of the company’s effort to maintain a differentiated portfolio in neurology and endocrine disorders.

Brekiya adds another potential contributor. Launched in the fourth quarter of 2025, it is positioned as the first and only auto-injector for severe migraine, and management cited peak sales potential of $50 million to $100 million. Early sales were modest in the launch quarter, but the product introduces incremental optionality as the Specialty portfolio evolves.

AMRX What to Watch in 2026 Guidance

The 2026 guideposts set clear markers for execution. Management guided total revenues of $3.05 billion to $3.1 billion, adjusted EBITDA of $720 million to $760 million (up 5% to 10%), and adjusted earnings per share of $0.93 to $1.03 (up 12% to 20%).

Investors should also track whether the FDA approval and launch cadence sustains the expected acceleration in Affordable Medicines, since that segment is targeted to carry a larger share of growth in 2026 while Specialty works through Rytary erosion.

In the broader generic-drug space, Teva Pharmaceutical Industries TEVA and Viatris VTRS currently carry Zacks Rank #3 (Hold), underscoring how estimate-driven sentiment can shift quickly in this industry and keeping execution and launch timing in focus across peers.

Amneal has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AMNEAL PHARMACEUTICALS, INC. Price and Consensus

 

AMNEAL PHARMACEUTICALS, INC. price-consensus-chart | AMNEAL PHARMACEUTICALS, INC. Quote

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com